These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

602 related articles for article (PubMed ID: 30415909)

  • 21. Glucagon-like peptide-1 receptor agonists and the risk of atrial fibrillation in adults with diabetes: a real-world study.
    Xu Y; Boyle TA; Lyu B; Ballew SH; Selvin E; Chang AR; Inker LA; Grams ME; Shin JI
    J Gen Intern Med; 2024 May; 39(7):1112-1121. PubMed ID: 38191976
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patient-important outcomes in type 2 diabetes: The paradigm of the sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists.
    Kintzoglanakis K; Diamantis C; Mariolis A; Paschou SA
    Diab Vasc Dis Res; 2024; 21(4):14791641241269743. PubMed ID: 39139128
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials.
    Patoulias D; Stavropoulos K; Imprialos K; Katsimardou A; Kalogirou MS; Koutsampasopoulos K; Zografou I; Papadopoulos C; Karagiannis A; Doumas M
    Diabetes Res Clin Pract; 2019 Dec; 158():107927. PubMed ID: 31733280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardio-renal outcomes and the direct medical cost of type 2 diabetes patients treated with sodium glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A population-based cohort study.
    Tang EHM; Wong CKH; Lau KTK; Fei Y; Cheung BMY
    Diabetes Res Clin Pract; 2021 Oct; 180():109071. PubMed ID: 34592391
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Practical Considerations and Rationale for Glucagon-Like Peptide-1 Receptor Agonist Plus Sodium-Dependent Glucose Cotransporter-2 Inhibitor Combination Therapy in Type 2 Diabetes.
    Goldenberg RM; Ahooja V; Clemens KK; Gilbert JD; Poddar M; Verma S
    Can J Diabetes; 2021 Apr; 45(3):291-302. PubMed ID: 33189580
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study.
    Kim HS; Yoon T; Jung CH; Park JY; Lee WJ
    Diabetes Metab J; 2022 Jul; 46(4):658-662. PubMed ID: 34743486
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives.
    Gurgle HE; White K; McAdam-Marx C
    Vasc Health Risk Manag; 2016; 12():239-49. PubMed ID: 27350752
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Geographic variation in sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide-1 receptor agonist use in people with type 2 diabetes in New South Wales, Australia.
    de Oliveira Costa J; Lin J; Milder TY; Greenfield JR; Day RO; Stocker SL; Neuen BL; Havard A; Pearson SA; Falster MO
    Diabetes Obes Metab; 2024 Jul; 26(7):2787-2795. PubMed ID: 38618983
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparative safety review between GLP-1 receptor agonists and SGLT2 inhibitors for diabetes treatment.
    Consoli A; Formoso G; Baldassarre MPA; Febo F
    Expert Opin Drug Saf; 2018 Mar; 17(3):293-302. PubMed ID: 29334278
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk of fracture with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in real-world use: systematic review and meta-analysis of observational studies.
    Hidayat K; Du X; Shi BM
    Osteoporos Int; 2019 Oct; 30(10):1923-1940. PubMed ID: 31134305
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of preceding drug therapy on the renal and cardiovascular outcomes of combined sodium-glucose cotransporter-2 inhibitor and glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes and chronic kidney disease.
    ; Tsukamoto S; Kobayashi K; Toyoda M; Tone A; Kawanami D; Suzuki D; Tsuriya D; Machimura H; Shimura H; Wakui H; Takeda H; Yokomizo H; Takeshita K; Chin K; Kanasaki K; Miyauchi M; Saburi M; Morita M; Yomota M; Kimura M; Hatori N; Nakajima S; Ito S; Murata T; Matsushita T; Furuki T; Hashimoto T; Umezono T; Muta Y; Takashi Y; Tamura K
    Diabetes Obes Metab; 2024 Aug; 26(8):3248-3260. PubMed ID: 38764356
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stroke Prevention by Antihyperglycemic Drugs in Type 2 Diabetes Mellitus.
    Albert SG; Shrestha E; Ahir V
    Endocr Pract; 2024 Mar; 30(3):246-252. PubMed ID: 38097111
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of Diabetes Medications Used by Adults With Commercial Insurance vs Medicare Advantage, 2016 to 2019.
    McCoy RG; Van Houten HK; Deng Y; Mandic PK; Ross JS; Montori VM; Shah ND
    JAMA Netw Open; 2021 Feb; 4(2):e2035792. PubMed ID: 33523188
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Similar effectiveness of dapagliflozin and GLP-1 receptor agonists concerning combined endpoints in routine clinical practice: A multicentre retrospective study.
    Fadini GP; Sciannameo V; Franzetti I; Bottigliengo D; D'Angelo P; Vinci C; Berchialla P; Arena S; Buzzetti R; Avogaro A;
    Diabetes Obes Metab; 2019 Aug; 21(8):1886-1894. PubMed ID: 30985052
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study.
    Chan YH; Chao TF; Chen SW; Lee HF; Li PR; Chen WM; Yeh YH; Kuo CT; See LC; Lip GYH
    Cardiovasc Diabetol; 2022 Jun; 21(1):118. PubMed ID: 35765074
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: A population-based cohort study.
    Dong YH; Chang CH; Lin JW; Yang WS; Wu LC; Toh S
    Diabetes Obes Metab; 2022 Aug; 24(8):1623-1637. PubMed ID: 35491533
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lowering Blood Pressure with the Combination of a Sodium-Glucose Cotransporter 2 Inhibitor and a Glucagon-like Peptide-1 Receptor Agonist in Type 2 Diabetic Patients: A Clinical Evidence.
    Arévalo-Lorido JC; Gómez JC; Huelgas RG; de Lucas DG; Polo LM; Aguilar JMV; Muñoz JE
    High Blood Press Cardiovasc Prev; 2018 Dec; 25(4):417-420. PubMed ID: 30251110
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sodium-glucose co-transporter 2 inhibitors & glucagon-like peptide-1 receptor agonists, efficacy & safety in diabetic kidney transplant recipients.
    Mahmoud T; Yagan J; Hasan A; Gheith OA; Mostafa M; Rida S; El-Serwi N; Shaker M; Khalid M
    Clin Transplant; 2023 Dec; 37(12):e15144. PubMed ID: 37755118
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes.
    Wright AK; Carr MJ; Kontopantelis E; Leelarathna L; Thabit H; Emsley R; Buchan I; Mamas MA; van Staa TP; Sattar N; Ashcroft DM; Rutter MK
    Diabetes Care; 2022 Apr; 45(4):909-918. PubMed ID: 35100355
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Health care utilization and costs associated with switching from DPP-4i to GLP-1RA or SGLT2i: an observational cohort study.
    Newman TV; Munshi KD; Neilson LM; Good CB; Swart ECS; Huang Y; Henderson R; Parekh N
    J Manag Care Spec Pharm; 2021 Apr; 27(4):435-443. PubMed ID: 33769857
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.